Jinghua Pharmaceutical (002349.SZ): Ji Desheng Snake Pills added additional shingles indications approved for drug clinical trials

Zhitongcaijing · 1d ago

Zhitong Finance App News, Jinghua Pharmaceutical (002349.SZ) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” (acceptance number: CXZL2600062; notification number: 2026LP03037) approved by the State Drug Administration, and the clinical trial application of the company Ji Desheng Snake Pills to increase function and treat shingles (hepatobiliary wet fever) was approved. Ji Desheng Snake Pills is the company's current marketed variety. The approval is the approval of a clinical trial application to increase the functional treatment of the Chinese drug that has already been marketed, and will not have a significant impact on the company's current business performance.